Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CorreGene Closes $14 Million Pre-A+ round for Novel TCR Drugs

publication date: Oct 31, 2022

Beijing CorreGene Biotechnology completed $14 million Pre-A+ financing round to develop new cancer drug using its cutting-edge T-cell receptor (TCR-T) platform. The company says TCR-T can target almost all proteins expressed by tumor cells while CAR-T drugs are limited to targeting antigens expressed on the surface of tumor cells. The platform re-engineers patients’ T cells with optimized TCR. CorreGene has two candidates in early-stage clinical trials. The round was co-led by Riverhead Capital and Xinrui Investment and included Longmen Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital